Compare Lionsgate Studios Corp Common Shares (LION) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs Smith & Nephew plc — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B), while Smith & Nephew plc trades at $27.9 (market cap $11.60B). The key difference: Smith & Nephew plc is far larger — about 3.5× Lionsgate Studios Corp Common Shares's market cap, and Smith & Nephew plc pays a 2.85% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Smith & Nephew plc for 121 Days on average.
| LION | SNN | |
|---|---|---|
Market Cap | $3.31B | $11.60B |
Volume | 2,146,134 | 971,836 |
Sector | Technology | Health |
52-Week High | $16.40 | $37.17 |
52-Week Low | $5.91 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $6.82B | $14.63B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
SNN trades at $27.88, near its 52-week low, with a mixed technical signal but improving fundamentals. Revenue grew to $6.16B in 2025, with net income margin expanding to 10.08%. Recent product launches like the EVOS PELVIC System and FLOW FLEXTEND COBLATION Wand highlight innovation, though the stock faces bearish moving averages and neutral oscillators.
Outlook is cautious; strong profitability and cash flow support value, but analyst consensus is predominantly Hold amid competitive pressures and recent CFO departure. Risks include execution challenges and debt levels, yet institutional interest from BlackRock's $505M investment signals confidence. The stock offers potential for recovery if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
